Grace Therapeutics (NASDAQ:GRCE) Stock Rating Upgraded by Zacks Research

Grace Therapeutics (NASDAQ:GRCE) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Grace Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Friday, July 17th. TD Cowen dropped their target price on shares of Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Finally, Craig Hallum set a $4.00 price objective on shares of Grace Therapeutics in a research report on Friday, April 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Grace Therapeutics Price Performance

Shares of NASDAQ:GRCE opened at $2.18 on Monday. The firm has a fifty day moving average price of $2.35 and a two-hundred day moving average price of $3.16. Grace Therapeutics has a one year low of $1.79 and a one year high of $5.18. The company has a market cap of $35.47 million, a price-to-earnings ratio of -4.54 and a beta of 0.39.

Grace Therapeutics (NASDAQ:GRCE) last released its quarterly earnings results on Thursday, June 18th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.17. Equities research analysts expect that Grace Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Grace Therapeutics

Institutional investors have recently made changes to their positions in the business. Eversept Partners LP bought a new position in shares of Grace Therapeutics during the 1st quarter valued at $3,503,000. Cerity Partners LLC bought a new position in shares of Grace Therapeutics during the fourth quarter valued at about $1,463,000. ADAR1 Capital Management LLC lifted its stake in shares of Grace Therapeutics by 83.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 641,988 shares of the company’s stock valued at $2,221,000 after acquiring an additional 291,538 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Grace Therapeutics by 87.9% during the 1st quarter. Renaissance Technologies LLC now owns 243,910 shares of the company’s stock valued at $1,129,000 after acquiring an additional 114,129 shares during the period. Finally, Pale Fire Capital SE bought a new position in Grace Therapeutics during the 1st quarter worth approximately $175,000. Hedge funds and other institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.